| Parameters |
Control |
Cholesterol-fed non-treated |
Cholesterol-fed Aliskiren-treated |
| SOD (IU/mL) |
22 ± 3.2 |
0.9 ± 0.01* |
45.3±5.6** |
| SBP (mmHg) |
100 ± 5.7 |
158 ± 3.4* |
90.5 ± 3.2** |
| TC (mg/dL) |
65.53 ± 5.43 |
255.4 ± 13.22* |
45.76 ± 3.44** |
| relaxation of aortic basal tone |
66.14 ± 12.16 |
87.43 ± 6.0* |
48.10 ± 10.23** |
| % mean relaxation of aortic basal tone from control group |
|
+32.19% |
-27.28% |
| % mean relaxation of aortic basal tone from cholesterol-fed non-treated group |
|
|
-44.98% |
Table 1 showed the results recorded at the end of 12th week therapy by aliskiren
regarding SOD enzyme in RBCs lysates, SBP, serum total cholesterol (TC) and
relaxation of the isolated aortic ring preparations by ACh. Treatment of cholesterolfed
rats group (3) significantly (p< 0.05) increased SOD enzyme level, reduced the
elevated SBP & serum total cholesterol (TC) and augmented relaxation responses
to ACh compared to cholesterol-fed non-treated group (2). The effects of aliskiren
were comparable to those reported with the control group (1).
• * p< 0.05 = significant decrease in SOD enzyme, while there is a significant
increase in mean SBP, serum total cholesterol (TC) and significant reduction
in relaxing effect of ACh in cholesterol-fed non-treated group (2) compared to
control group (1)
• ** p< 0.05 = significant increase in SOD enzyme, while significant decrease in
mean SBP, serum total cholesterol (TC) and significant augmentation in relaxing
effect of ACh in aliskiren-treated group (3) compared to cholesterol-fed nontreated
group (2). |
